At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 146 enrolled
Drug / intervention
CNTO 1275 63 mg +1 moredrug
Likely dose
CNTO 1275 63 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
In Brief
A Phase 2 clinical trial evaluating CNTO 1275 63 mg and Placebo for Psoriatic Arthritis. Completed, enrolled 146 participants across 25 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesCanada, Denmark, Finland, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedDec 2005
Primary CompletionMar 2007
Study CompletionSep 2007
TodayJul 2026
First PostedDec 22, 2005
Enrollment StartDec 1, 2005
Primary CompletionMar 1, 2007
Study CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.5 years ago
Interventions
CNTO 1275 63 mgdrug
The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
Placebodrug
The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection